financetom
Business
financetom
/
Business
/
Looking At Snowflake's Recent Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking At Snowflake's Recent Unusual Options Activity
Aug 14, 2025 9:28 AM

Whales with a lot of money to spend have taken a noticeably bearish stance on Snowflake.

Looking at options history for Snowflake we detected 12 trades.

If we consider the specifics of each trade, it is accurate to state that 16% of the investors opened trades with bullish expectations and 50% with bearish.

From the overall spotted trades, 4 are puts, for a total amount of $472,570 and 8, calls, for a total amount of $628,400.

What's The Price Target?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $180.0 and $220.0 for Snowflake, spanning the last three months.

Insights into Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Snowflake's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Snowflake's significant trades, within a strike price range of $180.0 to $220.0, over the past month.

Snowflake Call and Put Volume: 30-Day Overview

Biggest Options Spotted:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
SNOW PUT SWEEP NEUTRAL 09/19/25 $30.2 $29.85 $30.2 $220.00 $205.3K 1.5K 69
SNOW PUT SWEEP BEARISH 09/19/25 $30.2 $29.85 $30.2 $220.00 $181.2K 1.5K 69
SNOW CALL SWEEP BEARISH 09/05/25 $13.7 $13.55 $13.55 $195.00 $135.5K 547 11
SNOW CALL TRADE NEUTRAL 12/19/25 $25.45 $24.7 $25.13 $195.00 $125.6K 792 30
SNOW CALL SWEEP BULLISH 01/16/26 $23.25 $23.05 $23.25 $200.00 $95.3K 3.9K 43

About Snowflake

Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflake's cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The company's data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.

Following our analysis of the options activities associated with Snowflake, we pivot to a closer look at the company's own performance.

Present Market Standing of Snowflake

Currently trading with a volume of 1,113,888, the SNOW's price is down by -1.45%, now at $194.03.

RSI readings suggest the stock is currently may be approaching oversold.

Anticipated earnings release is in 13 days.

Expert Opinions on Snowflake

3 market experts have recently issued ratings for this stock, with a consensus target price of $257.0.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.

* Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Snowflake with a target price of $260.

* Reflecting concerns, an analyst from Stephens & Co. lowers its rating to Overweight with a new price target of $261.

* An analyst from UBS persists with their Buy rating on Snowflake, maintaining a target price of $250.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Snowflake, Benzinga Pro gives you real-time options trades alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
KazMunayGaz to ship 250,000 T of oil from Kashagan via Baku-Tbilisi-Ceyhan in 2025
KazMunayGaz to ship 250,000 T of oil from Kashagan via Baku-Tbilisi-Ceyhan in 2025
Jan 29, 2025
MOSCOW, Jan 29 (Reuters) - Kazakhstan's state energy company KazMunayGaz plans to export about 250,000 metric tons (5,400 barrels per day) of oil from Kashagan oilfield via the Baku-Tbilisi-Ceyhan pipeline in 2025, it said on Wednesday, seeking to bypass Russia. The offshore Kashagan field, one of the world's biggest discoveries in recent decades, is being developed by Eni , Shell,...
BMO, Mastercard, Porter Airlines to Launch VIPorter Credit Card in Spring 2025
BMO, Mastercard, Porter Airlines to Launch VIPorter Credit Card in Spring 2025
Jan 29, 2025
09:03 AM EST, 01/29/2025 (MT Newswires) -- BMO (BMO), Mastercard ( MA ) , and Porter Airlines said Wednesday they will introduce the BMO VIPorter Mastercard in the spring, allowing Canadians to earn and use travel rewards. The card will let users collect VIPorter points through consecutive spending, redeemable for flights within Porter's network, according to the companies. A pre-launch...
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Jan 29, 2025
Teva Pharmaceutical Industries ( TEVA ) shares are trading lower Wednesday on the heels of the company’s fourth-quarter financial results. Here’s what you need to know. What To Know: Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share, beating estimates of...
Takeda Pharmaceutical Says Hema-Quebec to Cover HyQvia for Immunodeficiency Treatment
Takeda Pharmaceutical Says Hema-Quebec to Cover HyQvia for Immunodeficiency Treatment
Jan 29, 2025
09:03 AM EST, 01/29/2025 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Wednesday that the non-profit organization Hema-Quebec will begin reimbursing HyQvia for patients with primary or secondary humoral immunodeficiencies aged two and older starting Jan. 30 in Quebec, Canada. The company said HyQvia, a subcutaneous immune globulin infusion indicated for immune system deficiencies that increase infection risk, received...
Copyright 2023-2026 - www.financetom.com All Rights Reserved